Letters, Testimony & Comments

April 26, 2007
The Statement of the The Biotechnology Industry Organization On H.R. 1908, The Patent Reform Act of 2007 The United States House of Representatives Committee on the Judiciary Subcommittee on Courts, the Internet, and Intellectual Property...
April 25, 2007
The paper details the legal and regulatory implications of the many important differences between biologics and traditional "small molecule" drugs.
April 17, 2007
Chairman Pallone, Ranking Member Deal, and members of the Health Subcommittee, thank you for the opportunity to testify before you today on the success of the Prescription Drug User Fee Act (PDUFA) and the proposed enhancements for PDUFA IV. My...
April 16, 2007
Regarding their letter to Pharmaceutical Manufacturers on the definition of AMP used to calculate 340B ceiling prices.
April 10, 2007
April 10th, 2007 The Honorable Harry Reid Majority Leader United States Senate Washington, DC 20510 Dear MR. Leader: As President & CEO of the Biotechnology Industry Organization (BIO), I am writing to express BIO’s support for...
April 3, 2007
BIO's Comments.
April 2, 2007
Comments regarding purchasing by state and local governments through Federal Supply Schedules.
March 29, 2007
Any Statutory Pathway for the Approval of Follow-On Biologics Must Protect Patient Safety and Preserve Incentives to Innovate
March 26, 2007
BIO Submits letter to Congress restating opposition to H.R. 1038.
March 15, 2007
RE: Inclusion of Prescription Drugs for Minimum Credible Coverage Dear Dr. Kingsdale: On behalf of the Biotechnology Industry Organization (BIO), I am writing regarding the Connector Board's recent endorsement of plans for Commonwealth...
March 15, 2007
BIO letter to the Commonwealth Health Insurance Connector Authority regarding the inclusion of prescription drugs for Minimum Creditable Coverage (MCC) under the Commonwealth Choice program.
March 13, 2007
Comments on the HRSA Notice
March 8, 2007
Office of the U.S. Trade Representative